{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:03:58Z","timestamp":1794956638514,"version":"4.9.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12879-016-2097-7","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T14:05:26Z","timestamp":1484316326000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Concomitant disseminated histoplasmosis and disseminated tuberculosis after tumor necrosis factor inhibitor treatment: a case report"],"prefix":"10.1186","volume":"17","author":[{"given":"Juan E.","family":"Mu\u00f1oz-Oca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha L.","family":"Villarreal Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aracelis","family":"Nieves-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lemuel","family":"Mart\u00ednez-Bonilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,13]]},"reference":[{"key":"2097_CR1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/B978-1-4160-5680-5.00015-3","volume-title":"Clinical mycology","author":"GM Anstead","year":"2009","unstructured":"Anstead GM, Patterson TF. Endemic mycoses. In: Anaissie EJ, McGinnis MR, Pfaller MA, editors. Clinical mycology. 2nd ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2009. p. 355\u201373.","edition":"2"},{"key":"2097_CR2","volume-title":"Global tuberculosis report","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. Global tuberculosis report. 2015. Available at: http:\/\/www.who.int\/tb\/publications\/global_report\/en\/. Accessed 16 April 2015."},{"key":"2097_CR3","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/imm.12223","volume":"141","author":"AJ Verrall","year":"2014","unstructured":"Verrall AJ, Netea MG, Alisjahbana B, Hill PC, van Crevel R. Early clearance of Mycobacterium tuberculosis: a new frontier in prevention. Immunology. 2014;141:506\u201313.","journal-title":"Immunology"},{"key":"2097_CR4","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.4269\/ajtmh.2012.12-0292","volume":"87","author":"CA Agudelo","year":"2012","unstructured":"Agudelo CA, Restrepo CA, Molina DA, et al. Tuberculosis and histoplasmosis co-infection in AIDS patients. Am J Trop Med Hyg. 2012;87:1094\u20138.","journal-title":"Am J Trop Med Hyg"},{"key":"2097_CR5","unstructured":"US Food and Drug Administration. Information for healthcare professionals: cimzia (certolizumab pegol), enbrel (etanercept), humira (adalimumab), and remicade (infliximab). Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124185.htm . Accessed: 16 Apr 2015."},{"key":"2097_CR6","unstructured":"Centers for Disease Control. Latent Tuberculosis Infection: A Guide for Primary Health Care Providers. Available at: https:\/\/www.cdc.gov\/tb\/publications\/ltbi\/pdf\/targetedltbi.pdf . Accessed: 16 Apr 2015."},{"key":"2097_CR7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ibd.21329","volume":"17","author":"BJ Qumseya","year":"2011","unstructured":"Qumseya BJ, Ananthakrishnan AN, Skaros S, et al. QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis. 2011;17:77\u201383.","journal-title":"Inflamm Bowel Dis"},{"key":"2097_CR8","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","volume":"48","author":"JJ Gomez-Reino","year":"2003","unstructured":"Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48:2122\u20137.","journal-title":"Arthritis Rheum"},{"key":"2097_CR9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1128\/CMR.00027-06","volume":"20","author":"CA Kauffman","year":"2007","unstructured":"Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev. 2007;20:115\u201332.","journal-title":"Clin Microbiol Rev"},{"key":"2097_CR10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s002280050437","volume":"54","author":"S Jaruratanasirikul","year":"1998","unstructured":"Jaruratanasirikul S, Sriwiriyajan S. Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. Eur J Clin Pharmacol. 1998;54:155\u20138.","journal-title":"Eur J Clin Pharmacol"},{"key":"2097_CR11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1043-6618(05)80021-0","volume":"32","author":"MS Benedetti","year":"1995","unstructured":"Benedetti MS. Inducing properties of rifabutin, and effects on the pharmacokinetics and metabolism of concomitant drugs. Pharmacol Res. 1995;32:177\u201387.","journal-title":"Pharmacol Res"},{"key":"2097_CR12","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(09)60333-0","volume":"373","author":"MB Conde","year":"2009","unstructured":"Conde MB, Efron A, Loredo C, et al. Moxifloxacin in the initial therapy of tuberculosis: a randomized, phase 2 trial. Lancet. 2009;373:1183\u20139.","journal-title":"Lancet"},{"key":"2097_CR13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jctube.2016.03.002","volume":"3","author":"M Lanzafame","year":"2016","unstructured":"Lanzafame M, Vento S. Tuberculosis-immune reconstitution inflammatory syndrome. J Clin Tuberc Other Mycobact Dis. 2016;3:6\u20139.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2097_CR14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jbspin.2015.04.022","volume":"83","author":"C Rivoisy","year":"2016","unstructured":"Rivoisy C, Tubach F, Roy C, et al. Paradoxical anti-TNF-associated TB worsening: Frequency and factors associated with IRIS. Joint Bone Spine. 2016;83:173\u20138.","journal-title":"Joint Bone Spine"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-016-2097-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T08:12:01Z","timestamp":1498378321000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-016-2097-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,13]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2097"],"URL":"https:\/\/doi.org\/10.1186\/s12879-016-2097-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,13]]},"article-number":"70"}}